Oleclumab clinical trials
Oleclumab is named as an intervention in 10 current clinical trials in our USA, France, Canada, South Korea, Spain, Taiwan, Belgium, Poland, Italy, Portugal, Turkey, UK, Germany, Australia, Austria, Ireland, China, Brazil, Japan and Israel registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is AstraZeneca (5). The most-studied condition is Non-Small Cell Lung Cancer.
How Oleclumab works
All drug targets →- 5'-nucleotidase inhibitor InhibitorTarget: NT5E 5'-nucleotidase ecto✓ In ChEMBL and the Guide to Pharmacology
- Non-small cell lung carcinomaPhase 3
- Breast cancerPhase 2
- Colorectal cancerPhase 2
- Head and neck squamous cell carcinomaPhase 2
- OsteosarcomaPhase 2
- Ovarian cancerPhase 2
- Pancreatic adenocarcinomaPhase 2
- Pancreatic ductal adenocarcinomaPhase 2
- Prostate cancerPhase 2
- Renal cell adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3990016, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9596, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Oleclumab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Oleclumab
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Oleclumab
9 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 5 |
| MedImmune LLC | 2 |
| Jules Bordet Institute | 2 |
| University Health Network, Toronto | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Oleclumab trials
How many clinical trials are testing Oleclumab?
10 current trials in our USA, France, Canada, South Korea, Spain, Taiwan, Belgium, Poland, Italy, Portugal, Turkey, UK, Germany, Australia, Austria, Ireland, China, Brazil, Japan and Israel registers name Oleclumab (also registered as MEDI9447) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Oleclumab trials recruiting patients?
Yes. 2 of the 10 trials are recruiting: 1 with sites in USA, 1 with sites in France, 2 with sites in Canada, 1 with sites in South Korea, 1 with sites in Spain, 1 with sites in Taiwan, 1 with sites in Belgium, 1 with sites in Italy, 1 with sites in Portugal, 1 with sites in Turkey and 1 with sites in Ireland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Oleclumab clinical trials?
AstraZeneca (5), MedImmune LLC (2), Jules Bordet Institute (2) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.
Are there Oleclumab clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Oleclumab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Oleclumab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Oleclumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.